John Ziegler - Quest Diagnostics Independent Director
| DGX Stock | USD 136.70 6.61 5.08% |
Director
Mr. John B. Ziegler is an Independent Director of Quest Diagnostics Inc. Mr. Ziegler retired in January 2006 as the President, Worldwide Consumer Healthcare of GlaxoSmithKline plc. He joined a predecessor company of GlaxoSmithKline in 1991, and held positions of increasing responsibility during his tenure. since 2000.
| Age | 69 |
| Tenure | 24 years |
| Address | 500 Plaza Drive, Secaucus, NJ, United States, 07094 |
| Phone | 973 520 2700 |
| Web | https://www.questdiagnostics.com |
John Ziegler Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Ziegler against Quest Diagnostics stock is an integral part of due diligence when investing in Quest Diagnostics. John Ziegler insider activity provides valuable insight into whether Quest Diagnostics is net buyers or sellers over its current business cycle. Note, Quest Diagnostics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Quest Diagnostics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Ziegler over three weeks ago Disposition of 969 shares by John Ziegler of Arch Resources at 185.78 subject to Rule 16b-3 | ||
John Ziegler over three months ago Sale by John Ziegler of 5000 shares of Arch Resources | ||
John Ziegler over six months ago Sale by John Ziegler of 1953 shares of Quest Diagnostics | ||
John Ziegler over a year ago Sale by John Ziegler of 100 shares of Arch Resources |
Quest Diagnostics Management Efficiency
The company has Return on Asset of 0.0621 % which means that on every $100 spent on assets, it made $0.0621 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1462 %, implying that it generated $0.1462 on every 100 dollars invested. Quest Diagnostics' management efficiency ratios could be used to measure how well Quest Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.14 in 2024. Return On Capital Employed is likely to drop to 0.10 in 2024. At this time, Quest Diagnostics' Other Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.99 in 2024, whereas Total Assets are likely to drop slightly above 8.5 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| William Hall | ICON PLC | 64 | |
| John Danhakl | IQVIA Holdings | 64 | |
| Dennis Gillings | IQVIA Holdings | 72 | |
| Mai Xiaoying | Twist Bioscience Corp | 30 | |
| Declan McKeon | ICON PLC | 63 | |
| Anne Szostak | IDEXX Laboratories | 67 | |
| Paul Clark | Agilent Technologies | 72 | |
| George Massaro | Charles River Laboratories | 73 | |
| George Scangos | Agilent Technologies | 72 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| Jan Johannessen | Twist Bioscience Corp | 62 | |
| George Milne | Mettler Toledo International | 71 | |
| Richard Francis | Mettler Toledo International | 52 | |
| Robert Chess | Twist Bioscience Corp | 61 | |
| Dermot Kelleher | ICON PLC | 58 | |
| George Llado | Charles River Laboratories | 55 | |
| Todd Sisitsky | IQVIA Holdings | 49 | |
| Frederick Craves | Twist Bioscience Corp | 72 | |
| Daniel Podolsky | Agilent Technologies | 67 | |
| Caspar Tudor | Waters | N/A | |
| Hugh Brady | ICON PLC | 57 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0621 |
Quest Diagnostics Leadership Team
Elected by the shareholders, the Quest Diagnostics' board of directors comprises two types of representatives: Quest Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quest. The board's role is to monitor Quest Diagnostics' management team and ensure that shareholders' interests are well served. Quest Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quest Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Plewman, Senior Services | ||
| Gail Wilensky, Independent Director | ||
| Kristin Esq, Senior Officer | ||
| Stephen Rusckowski, CEO and President Director and Member of Executive Committee | ||
| Wright Lassiter, Independent Director | ||
| Gary Pfeiffer, Independent Director | ||
| Vicky Gregg, Independent Director | ||
| Cecilia McKenney, Senior Officer | ||
| Helen Torley, Independent Director | ||
| Michael Prevoznik, Senior Vice President General Counsel | ||
| Tracey Doi, Independent Director | ||
| John Ziegler, Independent Director | ||
| Karthik Kuppusamy, Senior Solutions | ||
| John Baldwin, Independent Director | ||
| Jon Cohen, Senior Vice President Chief Medical Officer | ||
| Catherine Doherty, Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing | ||
| Manuel Mendez, Senior Vice President Chief Commercial Officer | ||
| Gabrielle Wolfson, Senior Vice President and Chief Information and Digital Officer | ||
| Carrie Manner, Senior Vice President - Advanced Diagnostics | ||
| Sam Samad, Executive CFO | ||
| Dermot Shorten, MA Strategy | ||
| Jenne Britell, Independent Director | ||
| Shawn Bevec, Executive Director Investor Relations | ||
| Dan Haemmerle, Executive Director - Investor Relations | ||
| Timothy Main, Independent Director | ||
| Michael Deppe, Vice President Corporate Controller and Chief Accounting Officer and Principal Accounting Officer | ||
| Everett Cunningham, Senior Vice President - Commercial | ||
| Mark Guinan, Chief Financial Officer, Executive Vice President | ||
| Daniel Stanzione, Non-Executive Chairman of the Board | ||
| Gary Samuels, Senior Officer | ||
| Denise Morrison, Independent Director | ||
| James Davis, Executive Vice President, General Diagnostics | ||
| Jeffrey Leiden, Independent Director | ||
| Timothy Ring, Lead Independent Director |
Quest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quest Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0621 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 19.32 B | ||||
| Shares Outstanding | 111.06 M | ||||
| Shares Owned By Insiders | 0.43 % | ||||
| Shares Owned By Institutions | 91.79 % | ||||
| Number Of Shares Shorted | 2.55 M | ||||
| Price To Earning | 14.57 X |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Quest Diagnostics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Quest Diagnostics information on this page should be used as a complementary analysis to other Quest Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Quest Stock analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Quest Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quest Diagnostics. If investors know Quest will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quest Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.868 | Dividend Share 2.84 | Earnings Share 7.49 | Revenue Per Share 82.607 | Quarterly Revenue Growth (0.02) |
The market value of Quest Diagnostics is measured differently than its book value, which is the value of Quest that is recorded on the company's balance sheet. Investors also form their own opinion of Quest Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Quest Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quest Diagnostics' market value can be influenced by many factors that don't directly affect Quest Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quest Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Quest Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quest Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.